DBV Technologies (DBVT) Change in Accured Expenses (2020 - 2026)

DBV Technologies (DBVT) posted quarterly Change in Accured Expenses of $3.1 million for Q2 2026, up 93.75% year-on-year from $1.6 million in Q2 2025, and up 165.96% on a QoQ basis from -$4.7 million in Q1 2026.

DBV Technologies (DBVT) Change in Accured Expenses (2020 - 2026) Analysis & Trends

DBV Technologies (DBVT) has reported Change in Accured Expenses for 7 consecutive years, with $3.1 million the latest figure, recorded in Q2 2026.

  • Quarterly Change in Accured Expenses rose 93.75% year-over-year to $3.1 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $6.4 million (up 344.98% YoY) and the FY2025 annual result came in at $6.5 million, up 1681.69% from the prior year.
  • Change in Accured Expenses grew to $3.1 million in Q2 2026 per DBVT's latest filing, from -$4.7 million in the prior quarter.
  • Over the last five years, Change in Accured Expenses for DBVT reached as high as $7.2 million in Q4 2025 and fell as low as -$4.7 million in Q1 2026.
  • A 5-year average of $5833.3 and a median of $603500.0 in 2023 frame the typical range for Change in Accured Expenses.
  • Annual changes were most pronounced in 2023 — Change in Accured Expenses plunged 178.35% — and 2024, when it soared 1463.16%.
  • Year by year, Change in Accured Expenses stood at $3.6 million in 2022, then tumbled by 178.35% to -$2.8 million in 2023, then soared by 157.09% to $1.6 million in 2024, then surged by 351.29% to $7.2 million in 2025, then plunged by 56.82% to $3.1 million in 2026.
  • According to Business Quant data, Change in Accured Expenses over the past three periods registered $3.1 million, -$4.7 million, and $7.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Accured Expenses (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 1.13 Mn
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn -16.82 Mn
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 23.10 Mn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 107.70 Mn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -16.74 Mn
10 DBV Technologies 267.50 Mn 92.60 Mn - 3.10 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 3.10 Mn
Jun 30, 2026 3.10 Mn
Mar 31, 2026 -4.70 Mn
Mar 31, 2026 -4.70 Mn
Dec 31, 2025 7.18 Mn
Dec 31, 2025 7.18 Mn
Sep 30, 2025 841,000.00
Sep 30, 2025 841,000.00
Jun 30, 2025 1.60 Mn
Jun 30, 2025 1.60 Mn
Mar 31, 2025 -3.10 Mn
Mar 31, 2025 -3.10 Mn
Dec 31, 2024 1.59 Mn
Dec 31, 2024 1.59 Mn
Sep 30, 2024 1.35 Mn
Sep 30, 2024 1.35 Mn
Jun 30, 2024 1.19 Mn
Jun 30, 2024 1.19 Mn
Mar 31, 2024 -3.77 Mn
Mar 31, 2024 -3.77 Mn